Elecoglipron and dapagliflozin together for adults with type 2 diabetes
Tests elecoglipron with dapagliflozin, versus each alone, in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Key facts
- Where
- Berlin, Damme, Deggingen, Duisburg, Essen, Falkensee, Frankfurt am Main, Hamburg, Köln, Leipzig, Muenster, Nittendorf, Pohlheim, Wallerfing, and Weinheim, GermanySee the 15 sites
- Phase
- Phase 3
Where in Germany
- Medizinisches Versorgungszentrum Am Bahnhof Spandau GbRBerlin, GermanyTaking people
- Praxisgemeinschaft DammeDamme, GermanyTaking people
- Medizinisches Versorgungszentrum Jung GbRDeggingen, GermanyTaking people
- StudyPoint Duisburg GbRDuisburg, GermanyTaking people
- Studienzentrum BocholderstrasseEssen, GermanyTaking people
- Diabetes FalkenseeFalkensee, GermanyTaking people
- IKF Pneumologie GmbH & Co. KGFrankfurt am Main, GermanyTaking people
- Diabeteszentrum Hamburg West (DZHW)Hamburg, GermanyTaking people
- Zentrum für klinischen ForschungKöln, GermanyTaking people
- Diabetologische Schwerpunktpraxis - BAG Dr. Täschner/ Dr. BonigutLeipzig, GermanyTaking people
- Institut fuer Diabetesforschung Muenster GmbHMuenster, GermanyTaking people
- Gemeinschaftspraxis NittendorfNittendorf, GermanyTaking people
- Centrum Fuer Diabetologie Und AllgemeinmedizinPohlheim, GermanyTaking people
- GP DRs. GroßkopfWallerfing, GermanyTaking people
- Atriumpraxis Dres. MoeckeschWeinheim, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07662109EU 2025-523941-81-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.Read full original descriptionShow less
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Inclusion: Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening; T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication; HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol); Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (New York Heart Association IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.